









Markets
/
Stocks
/
nasdaq-agen
/

Agenus Inc

AGEN

View Detailed Chart

5.405USD

+0.045+0.84%

Market hours （ET）Quotes delayed by 15 min

143.58MMarket Cap

LossP/E TTM



Agenus Inc

5.405

+0.045+0.84%

Overview Company Financials

Financials

Intraday

30m

Today

+0.84%

5 Days

-9.31%

1 Month

-10.96%

6 Months

+53.99%

Year to Date

+97.26%

1 Year

-4.00%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 5 analysts

HOLD

Current Rating

11.500

Target Price

114.55%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Agenus Inc

AGEN

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(5)

Neutral(2)

Buy(3)

Indicators

Sell(2)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.299

Neutral

RSI(14)

45.742

Neutral

STOCH(KDJ)(9,3,3)

7.769

Oversold

ATR(14)

0.508

Low Volatility

CCI(14)

-183.384

Sell

Williams %R

98.795

Oversold

TRIX(12,20)

0.617

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

5.802

Sell

MA10

5.929

Sell

MA20

5.989

Sell

MA50

5.205

Buy

MA100

3.766

Buy

MA200

3.593

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Ticker SymbolAGEN

CompanyAgenus Inc

CEODr. Garo H. Armen, Ph.D.

Websitehttps://agenusbio.com/